SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
MaxWell Biosciences CEO Faces Backlash After Openly Discriminating Against Men
Genetown
Why Biogen, bluebird bio and Xencor are 3 Stocks to Look at in November
November 3, 2016
 · 
2 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Deals
Here’s Why Biogen Should Buy Ionis Pharma
November 1, 2016
 · 
2 min read
Genetown
The Good (Celgene) And Bad (Biogen) Ways To Deliver Drug Revenue Growth
October 28, 2016
 · 
1 min read
Genetown
Novartis AG Is Challenging Biogen On Biogen’s Own Turf
October 27, 2016
 · 
1 min read
How Biogen Makes Most of Its Cash
Business
Biogen’s CEO Hunt Holds Company in Limbo
October 27, 2016
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Why Biogen’s Fate May Depend on Eli Lilly’s Alzheimer’s Data
October 27, 2016
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Genetown
Biogen Quietly Kills Autoimmune Program
October 26, 2016
 · 
3 min read
Business
Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug
October 25, 2016
 · 
1 min read
Business
What to Look Out for When Biogen, Vertex Report Q3 This Week
October 24, 2016
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More